Literature DB >> 11123351

Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells.

E Pál1, T Tabira, T Kawano, M Taniguchi, S Miyake, T Yamamura.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a Th1 cell-mediated autoimmune disease that can be protected against by stimulating regulatory cells. Here we examined whether EAE can be purposefully modulated by stimulating Valpha14 NK T cells with the CD1d-restricted ligand alpha-galactosylceramide (alpha-GC). EAE induced in wild-type C57BL/6 (B6) mice was not appreciably altered by injection of alpha-GC. However, EAE induced in IL-4 knockout mice and IFN-gamma knockout mice was enhanced or suppressed by alpha-GC, respectively. This indicates that the IL-4 and IFN-gamma triggered by alpha-GC may play an inhibitory or enhancing role in the regulation of EAE. We next studied whether NK T cells of wild-type mice may switch their Th0-like phenotype toward Th1 or Th2. Notably, in the presence of blocking B7.2 (CD86) mAb, alpha-GC stimulation could bias the cytokine profile of NK T cells toward Th2, whereas presentation of alpha-GC by CD40-activated APC induced a Th1 shift of NK T cells. Furthermore, transfer of the alpha-GC-pulsed APC preparations suppressed or enhanced EAE according to their ability to polarize NK T cells toward Th2 or Th1 in vitro. These results have important implications for understanding the role of NK T cells in autoimmunity and for designing a therapeutic strategy targeting NK T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123351     DOI: 10.4049/jimmunol.166.1.662

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 2.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 3.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 4.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

5.  IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset.

Authors:  Duygu Sag; Petra Krause; Catherine C Hedrick; Mitchell Kronenberg; Gerhard Wingender
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

6.  Synthesis and Biological Activities of 5-Thio-α-GalCers.

Authors:  Jingjing Bi; Jing Wang; Kai Zhou; Yuancheng Wang; Min Fang; Yuguo Du
Journal:  ACS Med Chem Lett       Date:  2015-02-11       Impact factor: 4.345

Review 7.  Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Luc Van Kaer; Lan Wu; Vrajesh V Parekh
Journal:  Immunology       Date:  2015-06-22       Impact factor: 7.397

8.  Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells.

Authors:  Vrajesh V Parekh; Lan Wu; Danyvid Olivares-Villagómez; Keith T Wilson; Luc Van Kaer
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

Review 9.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

10.  Regulatory roles for NKT cell ligands in environmentally induced autoimmunity.

Authors:  Jaya Vas; Jochen Mattner; Stewart Richardson; Rachel Ndonye; John P Gaughan; Amy Howell; Marc Monestier
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.